Tue, Sep 16, 2014, 8:49 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • rehdvm2004 rehdvm2004 Jul 28, 2013 6:02 PM Flag

    Arguing over stock manipulation at this point . . .

    is like screaming at the top of your lungs in a theater that someone farted!

    The issuance of more shares was carefully worded, "approved by the BOD" and approved by the shareholders several years ago under the Whitless/Transave merger. Some Longs cautioned other shareholders on this MB that this seemed to follow in the historic "rewarding before the fact" bonus/stock options/perks for lots of management personnel who "underperformed" and "underwhelmed" company investors. The names of the departed include Glover, LaBella, Drucker, Sharoky (demotion), Whitten, etc. All with golden parachutes. To even bring up the issue now is beneath childishness.

    INSM is now down to completing two clinical trials and funding the commercialization of same. Along the way, they may be able to get a master file completed on the liposome (natural pulmonary compound) as a carrier which will be bigger than amikacin liposome.

    This process takes longer than any pumper ever suggested (it was always weeks away) and it "flew in the face of the bashers" who BTW were also saying the process takes too long. Drug, biological and device regulations take years. According to the FDA, there have been two expedited NDA that have taken 27 and 28 months respectively and filled niches with "no currently approved therapies."

    Get real on this MB. INSM under Lewis is doing 500% better than any management team since 2007.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 6users liked this postsusers disliked this posts3Reply
      Arguing over stock manipulation at this point . . .
      by rehdvm2004 • Jul 28, 2013 6:02 PM Flag
      is like screaming at the top of your lungs in a theater that someone farted!

      The issuance of more shares was carefully worded, "approved by the BOD" and approved by the shareholders several years ago under the Whitless/Transave merger. Some Longs cautioned other shareholders on this MB that this seemed to follow in the historic "rewarding before the fact" bonus/stock options/perks for lots of management personnel who "underperformed" and "underwhelmed" company investors. The names of the departed include Glover, LaBella, Drucker, Sharoky (demotion), Whitten, etc. All with golden parachutes. To even bring up the issue now is beneath childishness.

      INSM is now down to completing two clinical trials and funding the commercialization of same. Along the way, they may be able to get a master file completed on the liposome (natural pulmonary compound) as a carrier which will be bigger than amikacin liposome.

      This process takes longer than any pumper ever suggested (it was always weeks away) and it "flew in the face of the bashers" who BTW were also saying the process takes too long. Drug, biological and device regulations take years. According to the FDA, there have been two expedited NDA that have taken 27 and 28 months respectively and filled niches with "no currently approved therapies."

      Get real on this MB. INSM under Lewis is doing 500% better than any management team since 2007.

    • You are a charlatan. You have been exposed as a liar on more than one occasion. You contribute zero value to this forum, and are motivated by purely selfish reasons - primarily a need for attention.

    • only a few posts that should be ignored.Lewis is doing any better than any management team because money is flowing into his pockets.

 
INSM
13.25-0.12(-0.90%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.